National employer selects dario cardiometabolic and glp-1 solutions to improve employee health

New client will use dario's integrated approach to support long-term behavior change for employees living with diabetes, pre-diabetes, hypertension and those taking a glp-1 medication new york , dec. 5, 2023 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, announced today a new contract to provide cardiometabolic and glp-1 solutions to a national employer (the "employer") beginning in january 2024.   the employer, a national logistics company, selected dario to deliver integrated support for employees living with diabetes, pre-diabetes, weight management and hypertension, while also providing a tailored experience for employees taking a glp-1 medication.
DRIO Ratings Summary
DRIO Quant Ranking